Request Trial
shutterstock-212899525
30 January 2015AmericasJudith Kim and Scott Schaller

After Alice: the two-step rule

Patent-eligible subject matter in the US includes four statutory categories defined in title 35, section 101 (§101) of the US code as “any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
10x Genomics settles suit with rival and targets DNA sequencing startup
12 May 2026   The dominant player in the spatial biology market has sued a San Diego-based life sciences company over its genetic analysis technology, as another lawsuit in its patent litigation campaign approaches conclusion.
Americas
Trade secrets, AI and the new scrutiny of big damages awards
11 May 2026   Trade secret filings in the US reached an all-time high in 2025—particularly those relating to AI. Jeff Farrow of Michelman Robinson explains the principles that courts are increasingly applying, and how companies on both sides of the ‘v’ can prepare.
Americas
WATCH: Interview with Mythili Markowski, director at Regeneron
8 May 2026   LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.


Editor's picks

From the courtroom: Hikma v Amarin SCOTUS oral arguments
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

Editor's picks

Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026
Europe
WIPR debuts Global In-House Elite 2026
26 March 2026
Biotechnology
mRNA litigation: Who’s winning, who’s filing, and what’s next
25 March 2026

More features

10x Genomics settles suit with rival and targets DNA sequencing startup
Trade secrets, AI and the new scrutiny of big damages awards
WATCH: Interview with Mythili Markowski, director at Regeneron
IP in the deal room: The risks that bite before, during and after closing
Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’
Kilpatrick adds tech patent litigator and China expert to Chicago office
US judge allows rare patent defence in ‘world’s smallest heart pump’ suit
WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA